IGF::OT::IGF - CORE INFRASTRUCTURE SUPPORT

IGF::OT::IGF - 核心基础设施支持

• 批准号: 9553428
• 负责人: HOWARD BAILEY
• 金额: $ 81.62万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-24 至 2018-09-23
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9553428
• 关键词: Clinical; Clinical Chemoprevention; Clinical Trials; Conduct Clinical Trials; Contractor; Data; Development; Division of Cancer Prevention; Drug Industry; Funding; Guidelines; Individual; Maintenance; Malignant Neoplasms; Molecular Target; Monitor; National Cancer Institute; Outcome; Performance; Phase; Prevention; Preventive; Protocols documentation; Request for Proposals; Research Infrastructure; Safety; Site; Specific qualifier value; Time; Visit; cancer prevention; clinically relevant; data management; interest; laboratory experiment; meetings; prevention clinical trial; programs; protocol development; Clinical; Clinical Chemoprevention; Clinical Trials; Conduct Clinical Trials; Contractor; Data; Development; Division of Cancer Prevention; Drug Industry; Funding; Guidelines; Individual; Maintenance; Malignant Neoplasms; Molecular Target; Monitor; National Cancer Institute; Outcome; Performance; Phase; Prevention; Preventive; Protocols documentation; Request for Proposals; Research Infrastructure; Safety; Site; Specific qualifier value; Time; Visit; cancer prevention; clinically relevant; data management; interest; laboratory experiment; meetings; prevention clinical trial; programs; protocol development

The National Cancer Institute (NCI), Division of Cancer Prevention (DCP) Phase 0/I/II Cancer Prevention Clinical Trials Program supports early clinical trials to rapidly evaluate the clinical activity and biologic effects of cancer preventive agents of interest to DCP. The agents to be studied shall include agents developed by the pharmaceutical industry and provided to DCP for collaborative development, commercially available agents, and agents developed by DCP. The objectives of this Task Order are to provide the core infrastructure to support the conduct of the clinical trials.

国家癌症研究所（NCI），癌症预防措施（DCP）阶段0/I/II癌症预防临床试验计划支持早期临床试验，以快速评估DCP感兴趣的预防癌症预防剂的临床活性和生物学作用。 要研究的代理应包括制药行业开发的代理商，并向DCP提供了合作开发，可商购代理以及由DCP开发的代理商。 该任务订单的目标是提供核心基础设施以支持临床试验的行为。